PROFOUND MEDICAL CORP (PROF)

Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow

Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow

TORONTO, April 22, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical...

Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

TORONTO, April 09, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical...

PROF Stock Earnings: Profound Medical Misses EPS, Beats Revenue for Q4 2023

PROF stock results show that Profound Medical missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

PROF Stock Earnings: Profound Medical Misses EPS, Beats Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Profound Medical (NASDAQ:PROF) just reported results for the fourth quarter of ...

Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results

Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results

TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical...

Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference

Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference

TORONTO, March 04, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical...

Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure

Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure

TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...

Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow

Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow

TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...

Profound Medical announces $2.94M non-brokered private placement (NASDAQ:PROF)

Profound Medical announces a non-brokered private placement, raising approximately $2.94M from Canadian institutional investors for company growth.

Profound Medical Announces Non-Brokered Private Placement

Profound Medical Announces Non-Brokered Private Placement

TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (

Profound Medical lays out Q4 and FY 2024 preliminary numbers (NASDAQ:PROF)

Profound Medical expects Q4 revenues of $1.9M to $2M, showing significant growth. FY revenues are projected to be $7.1M to $7.2M.

Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenues

Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenues

TORONTO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...

Profound Medical sells 2.67M shares at $7.50 in public offering (NASDAQ:PROF)

Profound Medical prices public offering of 2.67M common shares, raising $20M for continued development of advanced medical systems and global...

Profound Medical Announces Pricing of US$20 Million Public Offering of Common Shares

Profound Medical Announces Pricing of US$20 Million Public Offering of Common Shares

TORONTO, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”) today announced the pricing of its...

Profound Medical stock sinks on proposed public offering of common shares (NASDAQ:PROF)

Profound Medical announces public offering of common shares for funding development, commercialization, and general corporate purposes.

Profound Medical Announces Proposed Public Offering of Common Shares

Profound Medical Announces Proposed Public Offering of Common Shares

TORONTO, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”) is pleased to announce the...

Stifel starts coverage of Profound Medical with hold rating (NASDAQ:PROF)

Stifel initiated coverage of Profound Medical with a hold rating, citing hurdles in increasing adoption for its prostate ablation technology TULSA-PRO. Read more here.

Profound Medical (PROF) Shares Cross Above 200 DMA

Profound Medical to Participate in the Stifel 2023 Healthcare Conference

Profound Medical to Participate in the Stifel 2023 Healthcare Conference

TORONTO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...

Profound Medical Announces CMS Extension of Temporary ‘Code’ for TULSA to ASC Setting

Profound Medical Announces CMS Extension of Temporary ‘Code’ for TULSA to ASC Setting

TORONTO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...

Profound Medical Announces Third Quarter 2023 Financial Results

Profound Medical Announces Third Quarter 2023 Financial Results

TORONTO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...

Profound Medical to Release Third Quarter 2023 Financial Results on November 2 – Conference Call to Follow

Profound Medical to Release Third Quarter 2023 Financial Results on November 2 – Conference Call to Follow

TORONTO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...

Profound Medical 2023 Virtual Analyst & Investor Day Agenda

TORONTO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...